Researchers from the Sant Pau Research Institute (IR Sant Pau), in collaboration with Sant Pau Hospital and the Josep Carreras Leukaemia Research Institute, have developed an innovative CAR-T cell ...

Not all patients respond well to chimeric antigen receptor (CAR) T cell therapies, which reprogram a patient’s own immune cells to recognize and attack cancer. A way to optimize these treatments ...

Just a few weeks after conception, stem cells are already orchestrating the future structure of the human brain. A new ...

T cell therapy called AIC100, which targets the ICAM-1 protein, demonstrated encouraging responses and an acceptable safety ...

Cytotoxic T cells are star players in the adaptive immune system, enforcing protection against invading viruses or cancer cells. However, evidence has been mounting that the cells may also deal a ...

A copy of the presentation materials will be added to the“Publications” section of the Company's website at tscan.com once the presentation has concluded. About TScan Therapeutics, Inc.

Yescarta – a CD19-directed genetically modified autologous T-cell immunotherapy ... Gilead bolstered its position in the development of next-generation cancer cell therapies with a deal to ...

A research team has developed a novel strategy for isolating high-purity muscle stem cells (MuSCs), fibro-adipogenic progenitors (FAPs), and smooth muscle cells (SMCs) from porcine muscle tissue.